It is considered that the NAT2 slow acetylator phenotype would increase the prostate cancer risk because this phenotype would have reduced hepatic N-acetylation for detoxification of HAA carcinogens, thus increasing the chance of hepatic N-hydroxylation for activation [36]. This evidence concerns the gene NAT2 and prostate cancer.